Literature DB >> 33584348

Early Renal Vasodilator and Hypotensive Action of Epoxyeicosatrienoic Acid Analog (EET-A) and 20-HETE Receptor Blocker (AAA) in Spontaneously Hypertensive Rats.

Agnieszka Walkowska1, Luděk Červenka2,3, John D Imig4, John R Falck5, Janusz Sadowski1, Elżbieta Kompanowska-Jezierska1.   

Abstract

Cytochrome P450 (CYP-450) metabolites of arachidonic acid: epoxyeicosatrienoic acids (EETs) and 20-hydroxyeicosatetraenoic acid (20-HETE) have established role in regulation of blood pressure (BP) and kidney function. EETs deficiency and increased renal formation of 20-HETE contribute to hypertension in spontaneously hypertensive rats (SHR). We explored the effects of 14,15-EET analog (EET-A) and of 20-HETE receptor blocker (AAA) on BP and kidney function in this model. In anesthetized SHR the responses were determined of mean arterial blood pressure (MABP), total renal (RBF), and cortical (CBF) and inner-medullary blood flows, glomerular filtration rate and renal excretion, to EET-A, 5 mg/kg, infused i.v. for 1 h to rats untreated or after blockade of endogenous EETs degradation with an inhibitor (c-AUCB) of soluble epoxide hydrolase. Also examined were the responses to AAA (10 mg/kg/h), given alone or together with EET-A. EET-A significantly increased RBF and CBF (+30% and 26%, respectively), seen already within first 30 min of infusion. The greatest increases in RBF and CBF (by about 40%) were seen after AAA, similar when given alone or combined with EET-A. MABP decreased after EET-A or AAA but not significantly after the combination thereof. In all groups, RBF, and CBF increases preceded the decrease in MABP. We found that in SHR both EET-A and AAA induced renal vasodilation but, unexpectedly, no additive effect was seen. We suggest that both agents have a definite therapeutic potential and deserve further experimental and clinical testing aimed at introduction of novel antihypertensive therapy.
Copyright © 2021 Walkowska, Červenka, Imig, Falck, Sadowski and Kompanowska-Jezierska.

Entities:  

Keywords:  20-HETE antagonist; EET analog; epoxyeicosatrienoic acids; hypertension; soluble epoxide hydrolase

Year:  2021        PMID: 33584348      PMCID: PMC7876274          DOI: 10.3389/fphys.2021.622882

Source DB:  PubMed          Journal:  Front Physiol        ISSN: 1664-042X            Impact factor:   4.566


  36 in total

1.  Inhibition of soluble epoxide hydrolase improves the impaired pressure-natriuresis relationship and attenuates the development of hypertension and hypertension-associated end-organ damage in Cyp1a1-Ren-2 transgenic rats.

Authors:  Zuzana Honetschlägerová; Alexandra Sporková; Libor Kopkan; Zuzana Husková; Sung H Hwang; Bruce D Hammock; John D Imig; Herbert J Kramer; Petr Kujal; Zdenka Vernerová; Věra C Chábová; Vladimír Tesař; Luděk Cervenka
Journal:  J Hypertens       Date:  2011-08       Impact factor: 4.844

2.  Two pharmacological epoxyeicosatrienoic acid-enhancing therapies are effectively antihypertensive and reduce the severity of ischemic arrhythmias in rats with angiotensin II-dependent hypertension.

Authors:  Luděk Červenka; Zuzana Husková; Libor Kopkan; Soňa Kikerlová; Lenka Sedláková; Zdenka Vaňourková; Petra Alánová; František Kolář; Bruce D Hammock; Sung H Hwang; John D Imig; John R Falck; Janusz Sadowski; Elzbieta Kompanowska-Jezierska; Jan Neckář
Journal:  J Hypertens       Date:  2018-06       Impact factor: 4.844

Review 3.  Orally Active Epoxyeicosatrienoic Acid Analogs.

Authors:  William B Campbell; John D Imig; James M Schmitz; John R Falck
Journal:  J Cardiovasc Pharmacol       Date:  2017-10       Impact factor: 3.105

Review 4.  Arachidonic acid monooxygenase: Genetic and biochemical approaches to physiological/pathophysiological relevance.

Authors:  Jorge H Capdevila; Wenhui Wang; John R Falck
Journal:  Prostaglandins Other Lipid Mediat       Date:  2015-05-15       Impact factor: 3.072

5.  Increases in plasma trans-EETs and blood pressure reduction in spontaneously hypertensive rats.

Authors:  Houli Jiang; John Quilley; Anabel B Doumad; Angela G Zhu; John R Falck; Bruce D Hammock; Charles T Stier; Mairead A Carroll
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-03-11       Impact factor: 4.733

6.  5,6-epoxyeicosatrienoic acid mediates the enhanced renal vasodilation to arachidonic acid in the SHR.

Authors:  Silvia I Pomposiello; John Quilley; Mairead A Carroll; John R Falck; John C McGiff
Journal:  Hypertension       Date:  2003-08-25       Impact factor: 10.190

7.  Nitric oxide, superoxide and renal blood flow autoregulation in SHR after perinatal L-arginine and antioxidants.

Authors:  M P Koeners; S Racasan; H A Koomans; J A Joles; B Braam
Journal:  Acta Physiol (Oxf)       Date:  2007-05-30       Impact factor: 6.311

8.  Polymorphism in soluble epoxide hydrolase and blood pressure in spontaneously hypertensive rats.

Authors:  Myriam Fornage; Cruz A Hinojos; Barbara W Nurowska; Eric Boerwinkle; Bruce D Hammock; Christophe H P Morisseau; Peter A Doris
Journal:  Hypertension       Date:  2002-10       Impact factor: 10.190

9.  Epoxyeicosatrienoic acid analog attenuates the development of malignant hypertension, but does not reverse it once established: a study in Cyp1a1-Ren-2 transgenic rats.

Authors:  Šárka Jíchová; Libor Kopkan; Zuzana Husková; Šárka Doleželová; Jan Neckář; Petr Kujal; Zdenka Vernerová; Herbert J Kramer; Janusz Sadowski; Elzbieta Kompanowska-Jezierska; Rami N Reddy; John R Falck; John D Imig; Luděk Červenka
Journal:  J Hypertens       Date:  2016-10       Impact factor: 4.844

10.  Inhibition of soluble epoxide hydrolase is renoprotective in 5/6 nephrectomized Ren-2 transgenic hypertensive rats.

Authors:  Petr Kujal; Vera Čertíková Chábová; Petra Škaroupková; Zuzana Husková; Zdena Vernerová; Herbert J Kramer; Agnieszka Walkowska; Elzbieta Kompanowska-Jezierska; Janusz Sadowski; Kento Kitada; Akira Nishiyama; Sung H Hwang; Bruce D Hammock; John D Imig; Ludek Červenka
Journal:  Clin Exp Pharmacol Physiol       Date:  2014-03       Impact factor: 2.557

View more
  3 in total

1.  Blockade of 20-hydroxyeicosatetraenoic acid receptor lowers blood pressure and alters vascular function in mice with smooth muscle-specific overexpression of CYP4A12-20-HETE synthase.

Authors:  Kevin Agostinucci; Rebecca Hutcheson; Sakib Hossain; Jonathan V Pascale; Elizabeth Villegas; Frank Zhang; Adeniyi Michael Adebesin; John R Falck; Sachin Gupte; Victor Garcia; Michal Laniado Schwartzman
Journal:  J Hypertens       Date:  2022-03-01       Impact factor: 4.844

2.  Divergent roles of angiotensin II upon the immediate and sustained increases of renal blood flow following unilateral nephrectomy.

Authors:  Satoshi Shimada; Chun Yang; Theresa Kurth; Allen W Cowley
Journal:  Am J Physiol Renal Physiol       Date:  2022-02-28

3.  Epoxyeicosatrienoic Acid Analog and 20-HETE Antagonist Combination Prevent Hypertension Development in Spontaneously Hypertensive Rats.

Authors:  Iwona Baranowska; Olga Gawrys; Agnieszka Walkowska; Krzysztof H Olszynski; Luděk Červenka; John R Falck; Adeniyi M Adebesin; John D Imig; Elżbieta Kompanowska-Jezierska
Journal:  Front Pharmacol       Date:  2022-01-17       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.